Pancreatitis from GLP-1 Medications in Nebraska
Last Updated: April 1, 2026
Pancreatitis cases linked to GLP-1 medications are being filed by Nebraska residents. Nebraska's four-year statute of limitations for both personal injury and product liability claims gives Depo-Provera and GLP-1 plaintiffs more time than most states to evaluate and file their cases. The state's population is concentrated in the Omaha and Lincoln metro areas, while its rural western regions may face delayed medical diagnoses that make the discovery rule especially relevant. Nebraska's single federal district handles all pharmaceutical litigation for the state's 2 million residents.
Pancreatitis has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity. Nebraska residents who developed pancreatitis after using these drugs may qualify for compensation. The product liability statute of limitations in Nebraska is 4 years. Cases are pending in federal MDL, and attorneys handle claims on a contingency fee basis — no cost unless you win.
Pancreatitis and GLP-1 Medications
Pancreatitis is an inflammation of the pancreas that causes severe, often debilitating abdominal pain. For Nebraska residents who developed pancreatitis after using GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity, the condition can range from acute episodes requiring emergency hospitalization to chronic pancreatitis causing permanent organ damage. Acute pancreatitis can be life-threatening, with complications including pancreatic necrosis, organ failure, and sepsis. Even patients who recover from acute episodes may face recurring attacks, dietary restrictions, and long-term digestive problems.
The manufacturers of these medications — Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Trulicity) — are accused of failing to adequately warn patients and prescribing physicians about the risk of pancreatitis. Despite internal data and emerging clinical evidence suggesting a causal link, the drug labels did not include sufficient warnings about the severity and potential permanence of this condition.
For Nebraska residents, this means that if you developed pancreatitis while taking a GLP-1 medication, you may have a valid product liability claim. The federal multidistrict litigation (MDL 3094) is consolidating these cases for efficient pretrial proceedings, while preserving each plaintiff's individual right to trial.
Recognizing Pancreatitis from GLP-1 Drugs
If you are a Nebraska resident who used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity and experienced any of the following symptoms, you may have developed pancreatitis as a result:
Severe upper abdominal pain
Pain radiating to the back
Nausea and vomiting
Fever
Rapid pulse
Diagnosis
Pancreatitis is typically confirmed through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound). If you are experiencing symptoms but have not yet received a formal diagnosis, an attorney can help coordinate appropriate medical evaluation as part of your case. Having documented medical evidence strengthens your claim significantly.
Filing a Pancreatitis Claim in Nebraska
Nebraska residents who developed pancreatitis after using GLP-1 medications have specific legal options and deadlines. The statute of limitations for product liability claims in Nebraska is 4 years, and the personal injury statute of limitations is 4 years.
Importantly, Nebraska recognizes the discovery rule. This means the statute of limitations clock may not start until you knew or reasonably should have known that your pancreatitis was caused by a GLP-1 medication. Given that the scientific understanding of the link between these drugs and pancreatitis has evolved significantly in recent years, many Nebraska residents may still be within their filing window even if their injury occurred some time ago.
Cases may be filed in the Nebraska District Courts at the state level or in federal court through the District of Nebraska. Most GLP-1 injury cases are being coordinated through the federal MDL for pretrial proceedings.
Nebraska legal landscape: Nebraska applies modified comparative fault with a 50% bar. The state follows the Nebraska Product Liability Act, which incorporates strict liability for manufacturing defects but applies a negligence-based risk-utility analysis for design defect claims. Punitive damages are not available under Nebraska law. Residents in Omaha, Lincoln, and Bellevue and surrounding areas should consult with an attorney to evaluate their potential pancreatitis claim.
Personal Injury SOL
4 years
Product Liability SOL
4 years
Discovery Rule
Yes
GLP-1 Drugs Linked to Pancreatitis
The following GLP-1 receptor agonist medications have been linked to pancreatitis in ongoing litigation. If you used any of these drugs in Nebraska and developed pancreatitis, you may qualify for a claim:
Ozempic
Semaglutide injection by Novo Nordisk. Prescribed for type 2 diabetes.
Wegovy
Semaglutide injection by Novo Nordisk. Prescribed for weight management.
Mounjaro
Tirzepatide injection by Eli Lilly. Prescribed for type 2 diabetes and weight management.
Rybelsus
Oral semaglutide by Novo Nordisk. Prescribed for type 2 diabetes.
Saxenda
Liraglutide injection by Novo Nordisk. Prescribed for weight management.
Trulicity
Dulaglutide injection by Eli Lilly. Prescribed for type 2 diabetes.
Do You Qualify for a Pancreatitis Claim in Nebraska?
Nebraska residents may be eligible to file a pancreatitis claim if the following criteria apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity or another GLP-1 receptor agonist medication.
Diagnosed with Pancreatitis
You received a medical diagnosis of pancreatitis through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound).
Injury Occurred After Drug Use
Your pancreatitis developed after you began taking the GLP-1 medication, establishing a timeline consistent with causation.
Within Nebraska's Filing Deadline
Your claim falls within Nebraska's product liability statute of limitations (4 years). The discovery rule may extend this deadline. An attorney can evaluate your specific timeline.
Pancreatitis in Nebraska: FAQ
What is pancreatitis and how is it linked to GLP-1 medications in Nebraska?
Inflammation of the pancreas causing severe abdominal pain. GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity have been linked to an increased risk of developing this condition. Nebraska residents who were prescribed these medications and subsequently developed pancreatitis may be eligible to file a lawsuit seeking compensation for their injuries, medical expenses, and other damages.
What are the symptoms of pancreatitis caused by Ozempic or other GLP-1 drugs?
Common symptoms of pancreatitis include severe upper abdominal pain, pain radiating to the back, nausea and vomiting, fever, rapid pulse. If you experienced these symptoms after taking Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity in Nebraska, you should seek medical attention immediately and consider having your case evaluated for potential legal action.
How is pancreatitis diagnosed for purposes of a GLP-1 lawsuit?
Pancreatitis is typically diagnosed through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound). For Nebraska residents filing a GLP-1 injury claim, medical documentation confirming your diagnosis is important for establishing your case. If you have not yet been formally diagnosed but are experiencing symptoms, your attorney can help coordinate appropriate medical evaluation.
What is the statute of limitations for a pancreatitis claim in Nebraska?
In Nebraska, the statute of limitations for product liability claims is 4 years. Nebraska recognizes the discovery rule, meaning the filing deadline may start from when you discovered or should have discovered that your pancreatitis was caused by a GLP-1 medication. Consult with an attorney to determine your exact deadline.
What compensation can I receive for pancreatitis caused by GLP-1 drugs in Nebraska?
Nebraska residents who qualify may recover compensation for medical expenses (including emergency treatment, surgery, hospitalization, and rehabilitation), lost wages, pain and suffering, emotional distress, and diminished quality of life. The amount depends on the severity of your pancreatitis and its impact on your daily life.
Is there any cost to file a pancreatitis claim in Nebraska?
There is no upfront cost. Attorneys handling GLP-1 pancreatitis cases in Nebraska work on a contingency fee basis, meaning they only receive payment if you receive compensation through settlement or trial verdict. NuLegal's initial case review is completely free with no obligation.
Related Resources
Other GLP-1 Injuries in Nebraska
Nebraska Residents: Get Your Free Case Review
If you developed pancreatitis after using Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity, time may be limited. Nebraska's product liability statute of limitations is 4 years. Get a free, no-obligation evaluation today.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.